Skip to main content
SpringerLink
Log in

Aspirina in prevenzione primaria nel diabete mellito: rassegna delle evidenze e delle raccomandazioni

  • RASSEGNA
  • Published:
L'Endocrinologo Aims and scope

Sommario

Il diabete mellito aumenta tra 2 e 4 volte il rischio di complicanze cardiovascolari maggiori e richiede, pertanto, strategie precoci e aggressive di prevenzione cardiovascolare primaria che dovrebbero comprendere, oltre all’educazione a uno stile di vita sano, l’uso delle statine e di farmaci ipoglicemizzanti con effetti cardioprotettivi. Nell’ambito della prevenzione cardiovascolare primaria assistiamo da anni al dibattito sull’efficacia e la sicurezza dell’aspirina a basse dosi. Nonostante le evidenze non del tutto incoraggianti questo farmaco viene ampiamente prescritto ai soggetti diabetici, spesso in maniera impropria. Lo scopo di questo articolo è quello di fornire una rassegna critica delle evidenze e delle raccomandazioni sull’uso dell’aspirina in prevenzione cardiovascolare primaria nei diabetici e di proporre un approccio ragionato alla prescrizione di questo farmaco.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Bibliografia

  1. Diabetes T (2016) J Intellect Disabil 8:219–220, This issue

    Google Scholar 

  2. Sarwar N, Gao P, Kondapally Seshasai SR et al. (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215–2222

    Article  CAS  Google Scholar 

  3. Kannel WB, D’Agostino RB, Wilson PW et al. (1990) Diabetes, fibrinogen, and risk of cardiovascular disease: the framingham experience. Am Heart J 120:672–676

    Article  CAS  Google Scholar 

  4. Laakso M, Lehto S (1998) Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atherosclerosis 137(Suppl):S65–73

    Article  CAS  Google Scholar 

  5. Cavender MA, Steg PG, Smith SC et al. (2015) Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the reduction of atherothrombosis for continued health (REACH) registry. Circulation 132:923–931

    Article  Google Scholar 

  6. Rawshani A, Rawshani A, Franzén S et al. (2017) Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 376:1407–1418

    Article  Google Scholar 

  7. Nesto RW (2004) Correlation between cardiovascular disease and diabetes mellitus: current concepts. Am J Med 116:11–22

    Article  Google Scholar 

  8. Grant PJ (2007) Diabetes mellitus as a prothrombotic condition. J Intern Med 262:157–172

    Article  CAS  Google Scholar 

  9. Muniyappa R, Sowers JR (2013) Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord 14:5–12

    Article  CAS  Google Scholar 

  10. Falcon C, Pfliegler G, Deckmyn H, Vermylen J (1988) The platelet insulin receptor: detection, partial characterization, and search for a function. Biochem Biophys Res Commun 157:1190–1196

    Article  CAS  Google Scholar 

  11. Hwang DL, Yen CF, Nadler JL (1993) Insulin increases intracellular magnesium transport in human platelets. J Clin Endocrinol Metab 76:549–553

    CAS  PubMed  Google Scholar 

  12. Kim JA, Montagnani M, Kwang KK, Quon MJ (2006) Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 113:1888–1904

    Article  Google Scholar 

  13. Watala C, Golański J, Boncler MA et al. (1998) Membrane lipid fluidity of blood platelets: a common denominator that underlies the opposing actions of various agents that affect platelet activation in whole blood. Platelets 9:315–327

    Article  CAS  Google Scholar 

  14. Boden G, Rao AK (2007) Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. Curr Diab Rep 7:223–227

    Article  CAS  Google Scholar 

  15. Muscari A, De Pascalis S, Cenni A et al. (2008) Determinants of mean platelet volume (MPV) in an elderly population: relevance of body fat, blood glucose and ischaemic electrocardiographic changes. Thromb Haemost 99:1079–1084

    Article  CAS  Google Scholar 

  16. Vizioli L, Muscari S, Muscari A (2009) The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract 63:1509–1515

    Article  CAS  Google Scholar 

  17. Bowman L, Mafham M, Wallendszus K et al. (ASCEND Study Collaborative Group) (2018) Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 379:1529–1539

    Article  CAS  Google Scholar 

  18. Grodzinsky A, Arnold SV, Wang TY et al. (2016) Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy. Am Heart J 182:111–118

    Article  Google Scholar 

  19. Bhatt DL, Bonaca MP, Bansilal S et al. (2016) Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI. J Am Coll Cardiol 67:2732–2740

    Article  CAS  Google Scholar 

  20. Cavallari I, Maddaloni E, Gragnano F et al. (2021) Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. Intern Emerg Med 16(6):1583–1591

    Article  Google Scholar 

  21. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L et al. (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849–1860

    Article  Google Scholar 

  22. Ogawa H, Masafumi N, Takeshi M et al. (2008) Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes. JAMA 300(18):2134–2141

    Article  CAS  Google Scholar 

  23. The ASCEND Study Collaboration Group (2018) Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 379:11

    Article  Google Scholar 

  24. Belch J, MacCuish A, Campbell I et al. (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337:a1840.

    Article  Google Scholar 

  25. Saito Y, Okada S, Ogawa H et al. (2017) Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes: 10-year follow-up of a randomized controlled trial. Circulation 135(7):659–670

    Article  CAS  Google Scholar 

  26. Raber I, Mccarthy CP, Vaduganathan M et al. (2019) The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet 393:2155–2167

    Article  Google Scholar 

  27. Cosentino F, Grant PJ, Aboyans V et al. (2019) 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41(2):255–323

    Article  Google Scholar 

  28. Arnett DK, Blumenthal RS, Albert MA et al. (2019) 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 140:e596–e646

    PubMed  PubMed Central  Google Scholar 

  29. Goff DC, Lloyd-Jones DM, Bennett G et al. (2014) 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63:2935–2959

    Article  Google Scholar 

  30. Pignone M, Alberts MJ, Colwell JA et al. (2010) Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American diabetes association, a scientific statement of the American heart association, and an expert consensus document of the. Am Col Circ 121:2694–2701

    Google Scholar 

  31. American Diabetes Association (2019) Cardiovascular disease and risk management: standards of medical care in diabetes-2019. Care 42:S103–S123

    Google Scholar 

  32. McNeil JJ, Wolfe R, Woods RL et al. (2018) Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 379:1509–1518

    Article  CAS  Google Scholar 

  33. Rocca B, Patrono C (2020) Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a new perspective. Diabetes Res Clin Pract 160:108008

    Article  CAS  Google Scholar 

  34. Hijazi Z, Lindbäck J, Alexander JH et al. (2016) The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J 37:1582–1590

    Article  Google Scholar 

  35. Yoshida R, Ishii H, Morishima I et al. (2019) Performance of HAS-BLED, ORBIT, PRECISE-DAPT, and PARIS risk score for predicting long-term bleeding events in patients taking an oral anticoagulant undergoing percutaneous coronary intervention. J Cardiol 73:479–487

    PubMed  Google Scholar 

  36. Cholesterol Treatment Trialists’ (CTT) Collaborators, Mihaylova B, Emberson J et al. (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet, 380:581–590 (London, England)

    Article  CAS  Google Scholar 

  37. Armitage J (2007) The safety of statins in clinical practice, vol 370. Lancet, London, pp 1781–1790

    Google Scholar 

  38. Gerstein HC, Colhoun HM, Dagenais GR et al. (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394:121–130

    Article  CAS  Google Scholar 

  39. Gaziano JM, Brotons C, Coppolecchia R et al. (2018) Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 392:1036–1046

    Article  CAS  Google Scholar 

  40. Scally B, Emberson JR, Spata E et al. (2018) Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 3:231–241

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UOC Cardiologia, Policlinico Universitario Campus Bio-Medico, Roma, Italia

    Ilaria Cavallari, Aurelio De Filippis, Edoardo Nobile, Francesco Veneziano, Rosetta Melfi, Annunziata Nusca, Gian Paolo Ussia & Francesco Grigioni

Authors
  1. Ilaria Cavallari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aurelio De Filippis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edoardo Nobile
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francesco Veneziano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rosetta Melfi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Annunziata Nusca
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gian Paolo Ussia
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Francesco Grigioni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ilaria Cavallari.

Ethics declarations

Conflitto di interesse

Gli autori Ilaria Cavallari, Aurelio De Filippis, Edoardo Nobile, Francesco Veneziano, Rosetta Melfi, Annunziata Nusca, Gian Paolo Ussia e Francesco Grigioni dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori dichiarano di non aver eseguito studi sugli animali.

Additional information

Proposto da: Raffaella Buzzetti.

Nota della casa editrice

Springer Nature rimane neutrale in riguardo alle rivendicazioni giurisdizionali nelle mappe pubblicate e nelle affiliazioni istituzionali.

Informazioni Supplementari

I link al materiale elettronico supplementare sono elencati qui sotto.

(DOC 35 kB)

(DOC 32 kB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cavallari, I., De Filippis, A., Nobile, E. et al. Aspirina in prevenzione primaria nel diabete mellito: rassegna delle evidenze e delle raccomandazioni. L'Endocrinologo 22, 441–448 (2021). https://doi.org/10.1007/s40619-021-00954-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-021-00954-w

Parole chiave

Search

Navigation